基质
医学
危险系数
结直肠癌
肿瘤科
内科学
阶段(地层学)
泌尿科
癌症
胃肠病学
病理
置信区间
免疫组织化学
生物
古生物学
作者
A. Huijbers,Rob A.E.M. Tollenaar,Gabi W. van Pelt,Eliane C.M. Zeestraten,Susan Dutton,Christopher C. McConkey,Enric Domingo,Vincent T.H.B.M. Smit,Rachel Midgley,B. F. Warren,Elaine Johnstone,David Kerr,Wilma E. Mesker
标识
DOI:10.1093/annonc/mds246
摘要
BackgroundThe intra-tumor stroma percentage in colon cancer (CC) patients has previously been reported by our group as a strong independent prognostic parameter. Patients with a high stroma percentage within the primary tumor have a poor prognosis.Patients and methodsTissue samples from the most invasive part of the primary tumor of 710 patients (52% Stage II, 48% Stage III) participating in the VICTOR trial were analyzed for their tumor-stroma percentage. Stroma-high (>50%) and stroma-low (≤50%) groups were evaluated with respect to survival times.ResultsOverall and disease-free survival times (OS and DFS) were significantly lower in the stroma-high group (OS P<0.0001, hazard ratio (HR)=1.96; DFS P<0.0001, HR=2.15). The 5-year OS was 69.0% versus 83.4% and DFS 58.6% versus 77.3% for stroma-high versus stroma-low patients.ConclusionThis study confirms the intra-tumor stroma ratio as a prognostic factor. This parameter could be a valuable and low cost addition to the TNM status and next to current high-risk parameters such as microsatellite instability status used in routine pathology reporting. When adding the stroma-parameter to the ASCO criteria, the rate of ‘undertreated’ patients dropped from 5.9% to 4.3%, the ‘overtreated’ increased with 6.8% but the correctly classified increased with an additional 14%.
科研通智能强力驱动
Strongly Powered by AbleSci AI